Cambridge, United Kingdom
PharmEnable Therapeutics, founded in 2016, is a pioneering biopharmaceutical company operating at the cutting edge of Biotechnology, Life Sciences, and Pharmaceutical industries. Based in the United Kingdom and a spin-off from the University of Cambridge, the company is renowned for its slogan: "Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs".
The company employs a proprietary AI-enabled drug discovery platform called chemSEEK. By exploring uncharted chemical spaces, PharmEnable develops novel small molecules that deliver specificity and selectivity akin to antibodies. Their current therapeutic focus targets oncology and neurology, with a commitment to partnerships for wider disease areas where therapeutic access is challenging.
In May 2023, PharmEnable secured a £6.00M Seed Round investment from notable investors including Parkwalk Advisors, Martlet Capital, and MP Healthcare Venture Management.
Vividion Therapeutics, Inc.